Understanding and treating lung damage caused by COVID-19
Mechanisms and Treatment of SARS-CoV-2 induced Lung Endothelial Injury
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11017013
This study is looking at how the COVID-19 virus can harm the blood vessels in your lungs and cause serious breathing problems, and it's testing new ways to help heal that damage and improve treatments alongside vaccines.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11017013 on ClinicalTrials.gov |
What this research studies
This research investigates how the SARS-CoV-2 virus causes injury to the lung's blood vessels, which can lead to severe respiratory issues like Acute Lung Injury and Acute Respiratory Distress Syndrome. The team will explore the mechanisms behind this damage and test potential treatments that could help repair the lung tissue affected by the virus. By focusing on the spike protein of the virus and its interaction with specific receptors in the body, the research aims to identify new therapeutic strategies that could complement existing vaccination efforts.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced severe respiratory symptoms due to COVID-19, particularly those diagnosed with Acute Lung Injury or Acute Respiratory Distress Syndrome.
Not a fit: Patients who have not contracted COVID-19 or those with mild symptoms that do not require hospitalization may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve recovery and outcomes for patients suffering from severe COVID-19-related lung injuries.
How similar studies have performed: Other research has shown promise in targeting lung injury mechanisms in COVID-19, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: REHMAN, JALEES — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: REHMAN, JALEES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.